ViroCell Appoints John A Dawson CBE As Chairman Of The Board Of Administrators

ViroCell Biologics (“ViroCell”) right now pronounces the appointment of John A. Dawson CBE as Chairman of the Board of Administrators (“Chairman”).

ViroCell aspires to be the worldwide viral vector provider of alternative for novel cell and gene therapy medical trials. John’s appointment as Chairman additional validates the business opportunity for ViroCell and represents another main milestone as we construct towardsschanging into a worldwide market chief within the viral vector medical trial CDMO market.

John was Chief Govt Officer of Oxford Biomedica PLC (OXB) from 2008 to 2022 and through that interval grew the agency’s market capitalisation from £30 to at peak over £1.2 billion, bringing OXB to the FTSE 250. He has been recognised for his management,with many awards, including the Scrip Award for Govt of the 12 months, and the Mediscience Awards CEO of the 12 months.

In 2022 John was awarded a Commander of the Order of the British Empire (CBE) for companies to U.Okay. Life Science by HM Queen Elizabeth II, which was conferred by HM King Charles III.  

John’s pivotal appointment follows the strategic construct out of the government workforce in 2022 with the vital additions of Nick Maishman as Chief Working Officer (“COO”) and Susan B. Nichols as Chief Enterprise Officer (“CBO”).

John’s arrival follows the MHRA issuance of the GMP certificates for the Nice Ormond Avenue Hospital for Youngsters’s (GOSH) Zayed Centre for Analysis (ZCR). The ZCR homes a state-of-the-art GMP manufacturing facility, the place ViroCell’s vector manufacturing is predicated. The GOSH-ViroCell workforce have labored intensely over the past 18 months to attain this goal, which units the stage for addressing the worldwide viral vector manufacturing provide demand imbalance for novel cell and gene therapies.  

John W Hadden II, CEO at ViroCell, commented:
We’re honoured that John has be a part ofed our Board of Administrators. His community in cell and gene remedy shall be invaluable in serving to us develop vector market share, as shoppers search to de-risk their novel cell and gene remedy product candidates. John has an spectacular business and operational observe report, gained from constructing one of many first viral vector CDMOs. We look ahead to working intentlywith John and to his contributions to ViroCell’s progress in 2023 and past.”

John A Dawson CBE, Chairman at ViroCell, added:
I’m delighted to hitch ViroCell’s Board of Administrators as its Chairman to assist it become a international chief within the cell and gene remedy medical trials CDMO market. I am impressed by each the standard and expertise of ViroCell’s workforce and the velocity with which they have scaled the organisation. Now, with entry to state-of-the-art amenities, ViroCell stands prepared to start manufacturing and delivering vectors to shoppers. What makes ViroCell distinctive and stand out amongst different CDMOs is that its workforce’s observe report of designing and manufacturing vectors for medical trials over twenty yearslocations them among the many most educated and skilled vector groups on the planet. The variety of companions which have approached ViroCell for his or her vector wants is a significant main indicator of future success. I am excited to hitch the company.